PAHC Earnings

PAHC reported its FY2026Q1 earnings on 2025-11-05, showcasing a revenue of 363.90M against an estimate of 345.44M, resulting in a 5.35% surprise. The EPS was 0.73, surpassing the expected 0.59 by 23.73% . The stock experienced a 4.59% price change on the earnings day and a 10.16% change over the next five days, reflecting market reactions to the results.

Following PAHC's FY2026Q1 earnings announcement on 2025-11-05, the stock price moved by 4.59% on the day of the release. Over the subsequent five days, it saw a 10.16% change. Historically, PAHC's stock price tends to shift by an average of -6.89% in the 10 days leading up to earnings and +4.51% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate PAHC’s annual revenue to reach 364.42M, while the EPS is projected at 0.69. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.01% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between PAHC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.01%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, PAHC's stock price typically moves by -6.89% in the 10 days before its earnings and +4.51% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 0.69 and revenue of 364.42M.

The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like the Phibro Forward, which are expected to drive growth. Despite some concerns over inventory buildup and unclear management responses on specific details, the overall sentiment is positive due to robust margins, favorable market trends, and promising product launches. The positive reception of Restoris and share gains in key segments further bolster the outlook, suggesting a likely stock price increase in the short term.